InspireMD, Inc. (NSPR) Announces Positive Results from MASTER MGuard Stent Trial
Medical device company InspireMD today announced positive results from a multi-center randomized trial of its MGuard™ embolic protection stent technology used for emergency treatment of patients suffering from heart attacks. The company will present detailed results from the MASTER trial at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) meeting in Miami in October. Ofir Paz, InspireMD’s CEO, said the results signify a “key milestone” in the company’s history; the company pointed out that stents for heart attack patients are expected to make up $1.8 billion of stent sales, or nearly 30 percent of the $5.9 billion global stent market. The MASTER…